Table II.

Transplantation Outcome

	Summary of DLI Therapy		GVHD						Tumor Staging
			Acute
UPN	# DLI	Specifics	s	g	l	Gr	Late Acute	Chronic	day +28	day +60	day +100	Overall Outcome
01	3	T-Rapa Series	0	0	0	0	G	N.E.	SD	SD	PD	Death (d 131) RCC
02	4	T-Rapa Series + Standard DLI (1)	1	0	0	I	None	V-V	SD	SD	PD	Death (d 740) RCC
03	3	T-Rapa Series	0	0	0	0	N.E.	N.E.	SD	PD	PD	Death (d 134) RCC
04	7	T-Rapa Series + Standard DLI (4)	0	0	0	0	S, G, L	None	SD	SD	PD	Death (d 303) Infection, GVHD, RCC
05	5	T-Rapa Series + Standard DLI (2)	0	0	0	0	N.E.	N.E.	SD	SD	PD	Death (d 127) RCC
06	4	T-Rapa Series + Standard DLI (1)	0	0	0	0	S	None	SD	SD	SD	Alive (d +1591)
07	2	T-Rapa #1, #2	0	0	0	0	S	N.E.	SD	PD	PD	Death (d 165) RCC
08	5	T-Rapa Series + Standard DLI (2)	0	0	0	0	None	None	SD	SD	PD	Death (d 300) RCC
09	4	T-Rapa Series + Standard DLI (1)	0	0	0	0	N.E.	N.E.	SD	PD	PD	Death (d 143) RCC
10	1	T-Rapa #1	2	0	0	I	N.E.	N.E.	SD	PD	NA	Death (d 78) RCC

^aAbbreviations: T-Rapa Series, indicates patient received T-Rapa cells at day 0 of transplant and at days 14 and 45 post-transplant; Standard DLI, indicates donor lymphocyte infusion consisting of unmanipulated donor T cells; N.E., not evaluable; N.A., not applicable; S, G, L indicates skin, gut, or liver acute GVHD; V-V, indicates vulvar vaginal chronic GVHD; SD, indicates stable disease; PD, indicates progressive disease; RCC, indicates disease active at time of death (SD or PD).

^bPatients UPN07 and UPN10 did not receive all T-Rapa infusions due to poor performance status.